Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Catalyst Pharmaceuticals Inc. shares valued at $40,646 were sold by INGENITO GARY on Jun 22. At $6.61 per share, INGENITO GARY sold 6,152 shares. The insider’s holdings dropped to 22,053 shares worth approximately $0.24 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
Also, INGENITO GARY sold 143,848 shares, netting a total of over 948,678 in proceeds. Following the sale of shares at $6.59 each, the insider now holds 22,053 shares.
Before that, INGENITO GARY had sold 3,612 shares from its account. In a trade valued at $25,237, the Chief Medical Officer traded Catalyst Pharmaceuticals Inc. shares for $6.99 each. Upon closing the transaction, the insider’s holdings decreased to 3,612 shares, worth approximately $0.24 million.
As published in their initiating research note from Cantor Fitzgerald on September 21, 2018, Catalyst Pharmaceuticals Inc. [CPRX] has been an Overweight. As of October 05, 2016, Piper Jaffray has increased its “Neutral” rating to a “an Overweight” for CPRX. Earlier on April 26, 2016, Piper Jaffray downgraded its rating. Their new recommendation was “a Neutral” for CPRX stock which previously was a “an Overweight”.
Analyzing CPRX’s Price Performance
On Thursday, Catalyst Pharmaceuticals Inc. [NASDAQ: CPRX] rose 2.57% to $10.77. The stock’s lowest price that day was $10.45, but it reached a high of $10.91 in the same session. During the last five days, there has been a surge of approximately 1.60%. Over the course of the year, Catalyst Pharmaceuticals Inc. shares have jumped approximately 59.08%. Shares of the company reached a 52-week high of $10.91 on 08/04/22 and a 52-week low of $5.24 on 01/28/22. A 50-day SMA is recorded $7.91, while a 200-day SMA reached $7.30. Nevertheless, trading volume fell to 1.39 million shares from 1.88 million shares the previous day.
Support And Resistance Levels for Catalyst Pharmaceuticals Inc. (CPRX)
According to the 24-hour chart, there is a support level at 10.51, which, if violated, would cause prices to drop to 10.25. In the upper region, resistance lies at 10.97. The next price resistance is at 11.17. RSI (Relative Strength Index) is 76.32 on the 14-day chart, showing overbought technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.60, which suggests the price will decrease in the coming days. Percent R is at 6.11%, indicating bullish price movement. Stochastics %K at selling indicates that the stock is to be held.
Is Catalyst Pharmaceuticals Inc. subject to short interest?
Stocks of Catalyst Pharmaceuticals Inc. saw a sharp steep in short interest on Jul 14, 2022 dropping by -0.93 million shares to 8.84 million. Data from Yahoo Finance shows that the short interest on Jun 14, 2022 was 9.77 million shares. A decline of -10.52% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 5.99 of the overall float, the days-to-cover ratio (short ratio) decline to 5.99.
Which companies own the most shares of Catalyst Pharmaceuticals Inc. (CPRX)?
In terms of Catalyst Pharmaceuticals Inc. share price expectations, FactSet research, analysts set an average price target of $11.60 in the next 12 months, up nearly 14.29% from the previous closing price of $10.50. Analysts anticipate Catalyst Pharmaceuticals Inc. stock to reach $15.00 by 2022, with the lowest price target being $9.00. In spite of this, 5 analysts ranked Catalyst Pharmaceuticals Inc. stock as a Buy at the end of 2022. On September 30, 2014, ROTH Capital assigned a price target of “a Buy” to the stock and reiterated coverage with a $6.